跳至主要内容
临床试验/NCT05526404
NCT05526404已完成不适用

Mobile Application Based Lactulose Titration for Prevention of Hepatic Encephalopathy

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年9月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
50
试验地点
1
主要终点
Achievement of daily stool goal

研究概览

简要总结

This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Ability to provide written, informed consent.
  • •Currently taking lactulose daily for prevention of hepatic encephalopathy.

排除标准

  • •Recent change in dosing of opioid medication.
  • •Previous Colorectal Surgery.
  • •Active diarrheal illness.
  • •Lack of smartphone or other smart device at home.

研究组 & 干预措施

Mobile application-based Bristol stool scale

Experimental

Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application

干预措施: Dieta mobile application (Other)

结局指标

主要结局

Achievement of daily stool goal

时间窗: 4 weeks

Number of subject to achieve daily stool goal, determined if use of the mobile application leads to improved rates of meeting daily stool goal (3-4 stools per day of Bristol Stool Scale 3-4)

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Douglas (Doug) A. Simonetto

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验